V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Peter J. Campbell; Martin Griesshammer; Konstanze Döhner; Hartmut Döhner; Rajko Kusec; Hans C. Hasselbalch; Thomas Stauffer Larsen; Niels Pallisgaard; Stéphane Giraudier; Marie Caroline Le Bousse-Kerdilès; Christophe Desterke; Bernadette Guerton; Brigitte Dupriez; Dominique Bordessoule; Pierre Fenaux; Jean Jacques Kiladjian; Jean François Viallard; Jean Brière; Claire N. Harrison; Anthony R. Green; John T. Reilly

doi:10.1182/blood-2005-08-3395

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Peter J. Campbell, Martin Griesshammer, Konstanze Döhner, Hartmut Döhner, Rajko Kusec, Hans C. Hasselbalch, Thomas Stauffer Larsen, Niels Pallisgaard, Stéphane Giraudier, Marie Caroline Le Bousse-Kerdilès, Christophe Desterke, Bernadette Guerton, Brigitte Dupriez, Dominique Bordessoule, Pierre Fenaux, Jean Jacques Kiladjian, Jean François Viallard, Jean Brière, Claire N. Harrison, Anthony R. GreenJohn T. Reilly^*

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Artikel › Forskning › peer review

Abstract

Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01).

Originalsprog	Engelsk
Sider (fra-til)	2098-2100
Antal sider	3
Tidsskrift	Blood
Vol/bind	107
Udgave nummer	5
DOI	https://doi.org/10.1182/blood-2005-08-3395
Status	Udgivet - 1 mar. 2006

Adgang til dokumentet

10.1182/blood-2005-08-3395

Andre filer og links

http://www.scopus.com/inward/record.url?scp=33344471678&partnerID=8YFLogxK

Citationsformater

Campbell, P. J., Griesshammer, M., Döhner, K., Döhner, H., Kusec, R., Hasselbalch, H. C., Larsen, T. S., Pallisgaard, N., Giraudier, S., Le Bousse-Kerdilès, M. C., Desterke, C., Guerton, B., Dupriez, B., Bordessoule, D., Fenaux, P., Kiladjian, J. J., Viallard, J. F., Brière, J., Harrison, C. N., ... Reilly, J. T. (2006). V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood, 107(5), 2098-2100. https://doi.org/10.1182/blood-2005-08-3395

@article{a2142ae26ff84638b7d7275de0a5400c,

title = "V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis",

abstract = "Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01).",

author = "Campbell, {Peter J.} and Martin Griesshammer and Konstanze D{\"o}hner and Hartmut D{\"o}hner and Rajko Kusec and Hasselbalch, {Hans C.} and Larsen, {Thomas Stauffer} and Niels Pallisgaard and St{\'e}phane Giraudier and {Le Bousse-Kerdil{\`e}s}, {Marie Caroline} and Christophe Desterke and Bernadette Guerton and Brigitte Dupriez and Dominique Bordessoule and Pierre Fenaux and Kiladjian, {Jean Jacques} and Viallard, {Jean Fran{\c c}ois} and Jean Bri{\`e}re and Harrison, {Claire N.} and Green, {Anthony R.} and Reilly, {John T.}",

year = "2006",

month = mar,

day = "1",

doi = "10.1182/blood-2005-08-3395",

language = "English",

volume = "107",

pages = "2098--2100",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

Campbell, PJ, Griesshammer, M, Döhner, K, Döhner, H, Kusec, R, Hasselbalch, HC, Larsen, TS, Pallisgaard, N, Giraudier, S, Le Bousse-Kerdilès, MC, Desterke, C, Guerton, B, Dupriez, B, Bordessoule, D, Fenaux, P, Kiladjian, JJ, Viallard, JF, Brière, J, Harrison, CN, Green, AR & Reilly, JT 2006, 'V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis', Blood, bind 107, nr. 5, s. 2098-2100. https://doi.org/10.1182/blood-2005-08-3395

TY - JOUR

T1 - V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

AU - Campbell, Peter J.

AU - Griesshammer, Martin

AU - Döhner, Konstanze

AU - Döhner, Hartmut

AU - Kusec, Rajko

AU - Hasselbalch, Hans C.

AU - Larsen, Thomas Stauffer

AU - Pallisgaard, Niels

AU - Giraudier, Stéphane

AU - Le Bousse-Kerdilès, Marie Caroline

AU - Desterke, Christophe

AU - Guerton, Bernadette

AU - Dupriez, Brigitte

AU - Bordessoule, Dominique

AU - Fenaux, Pierre

AU - Kiladjian, Jean Jacques

AU - Viallard, Jean François

AU - Brière, Jean

AU - Harrison, Claire N.

AU - Green, Anthony R.

AU - Reilly, John T.

PY - 2006/3/1

Y1 - 2006/3/1

N2 - Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01).

AB - Most patients with polycythemia vera and half with idiopathic myelofibrosis and essential thrombocythemia have an acquired V617F mutation in JAK2. Using sensitive polymerase chain reaction (PCR)-based methods, we genotyped 152 patients with idiopathic myelofibrosis to establish whether there were differences in presentation and outcome between those with and those without the mutation. Patients positive for V617F had higher neutrophil and white cell counts (P = .02) than did patients negative for V617F, but other diagnostic features were comparable between the 2 groups. Patients positive for V617F were less likely to require blood transfusion during follow-up (P = .03). Despite this, patients positive for V617F had poorer overall survival, even after correction for confounding factors (P = .01).

UR - http://www.scopus.com/inward/record.url?scp=33344471678&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-08-3395

DO - 10.1182/blood-2005-08-3395

M3 - Article

C2 - 16293597

AN - SCOPUS:33344471678

SN - 0006-4971

VL - 107

SP - 2098

EP - 2100

JO - Blood

JF - Blood

IS - 5

ER -

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

Abstract

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater